公司資料
Design Therapeutics 股價、新聞與催化劑
- 股票代碼:
- DSGN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
14.99 USD (-3.66%)
收盤價
最後更新: 2026年8月21日
635M USD
市值
股價為何變動
As of Aug 21, 2026, DSGN closed down 3.66% at $14.99. No new same-company headline was identified in the current news window.
公司概覽
GeneTAC Platform
Design Therapeutics develops GeneTAC small molecules that bind genomic repeat sequences and modulate transcription. The platform is designed either to increase expression of a deficient gene or reduce expression of a toxic mutant gene.
DT-216P2
DT-216P2 is being developed for Friedreich ataxia and is designed to increase endogenous frataxin expression. The Phase 1/2 RESTORE-FA trial measures safety, pharmacokinetics and changes in frataxin RNA and protein in blood and muscle.
DT-168
DT-168 is in a Phase 2 biomarker trial for Fuchs endothelial corneal dystrophy. The study evaluates corneal-endothelium biomarkers in patients already scheduled for transplant surgery.
DT-818
DT-818 is designed to selectively reduce transcription of the mutant DMPK allele in myotonic dystrophy type 1. A Phase 1 multiple-ascending-dose trial will assess safety and correction of disease-associated RNA mis-splicing.
Earlier Genetic-Disease Pipeline
Design is also characterizing GeneTAC candidates for Huntington’s disease and conducting discovery work across additional genomic disorders.
未來催化劑
- Initial dosing in the Phase 1 DT-818 trial planned in the first half of 2026, with results expected in 2027.
- DT-216P2 frataxin biomarker update expected in the second half of 2026.
- Phase 2 biomarker data for DT-168 expected in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。